Aranesp, Procrit Reimbursement Support Could Raise Kickback Issues – IG
Executive Summary
An IG advisory opinion rejecting a proposed patient support program for Aranesp (darbepoetin) helps clarify limits of competition in the chronic renal failure market, Amgen maintains